GSK’s Shingrix Vaccine Can Reach Millions More
US FDA Clears New Claim In Immunocompromised Adults
Executive Summary
The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.
You may also be interested in...
BioNTech Deal Shows Pfizer Is Reinvesting COVID-19 Windfall In mRNA
The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.
Vaxneuvance, Prevnar 20 Earn CDC Cmte Nod For Age- And Risk-Based Use; Broader Shingrix Use Supported
ACIP votes unanimously to recommend Merck and Pfizer’s pneumococcal vaccines in elderly and immunocompromised adults; GSK’s herpes zoster vaccine also gets unanimous nod for immunocompromised adults.
GSK Exceeds Expectations In Q2, But Still Awaiting Shingrix Bounce Back
While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.